Humeniuk, Michael S.
Gupta, Rajan T.
Healy, Patrick
McNamara, Megan
Ramalingam, Sundhar
Harrison, Michael
George, Daniel
Zhang, Tian
Wu, Yuan
Armstrong, Andrew J. http://orcid.org/0000-0001-7012-1754
Article History
Received: 21 June 2017
Revised: 2 August 2017
Accepted: 20 August 2017
First Online: 11 December 2017
Competing interest
: A.J.A. reports research funding (to Duke) from Medivation/Astellas, Bayer, Dendreon, and Janssen, Active Biotech, sanofi aventis, Gilead, Novartis, and Pfizer, and consulting/speaking with Dendreon and Sanofi aventis, consulting with Medivation/Astellas and Janssen. M.R.H. reports research funding (to Duke) from Medivation/Astellas, Acerta, Bristol Myers Squibb, Exelixis, Janssen, and Genentech; and consulting/speaking with Dendreon, Genentech, Exelixis, and Sanofi Aventis. D.J.G. reports research support from Janssen, Acerta, Millennium, Celldex, consulting with Acceleron Pharma, Astellas/Medivation, BioPharm Communications; consulting/research support from Bristol Myers Squibb Co, Exelixis Inc, Genentech, Innocrin, Pfizer Inc; and consulting/speaking/research support from Bayer Healthcare Pharmaceuticals, Dendreon Corporation, Novartis, and Sanofi Aventis. T.Z. reports research support from Janssen, Acerta, and Pfizer. R.T.G. reports consulting with Bayer Pharma AG, Halyard Health and Invivo Corp. as well as speakers bureau with Bayer Pharma AG. M.McN. reports research funding (to Duke) from Medivation/Astellas, Janssen, and Bayer Healthcare Pharmaceuticals.